Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2022 | May 11, 2022 | |
Document Type | 10-Q | |
Entity Central Index Key | 0001534248 | |
Document Period End Date | Mar. 31, 2022 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity File Number | 001-38807 | |
Entity Registrant Name | Chemomab Therapeutics Ltd. | |
Entity Incorporation, State or Country Code | L3 | |
Entity Tax Identification Number | 81-3676773 | |
Entity Address, Address Line One | Kiryat Atidim | |
Entity Address, Address Line Two | Building 7 | |
Entity Address, City or Town | Tel Aviv | |
Entity Address, Postal Zip Code | 6158002 | |
Entity Address, Country | IL | |
City Area Code | 972 | |
Local Phone Number | 77-331-0156 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 11,404,515 | |
American Depositary Shares [Member] | ||
Title of 12(b) Security | American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share | |
Trading Symbol | CMMB | |
Name of Exchange on which Security is Registered | NASDAQ | |
Ordinary Shares, No Par Value Per Share [Member] | ||
Title of 12(b) Security | Ordinary shares, no par value per share | |
Trading Symbol | n/a | |
Name of Exchange on which Security is Registered | NASDAQ |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | |
Current assets | |||
Cash and cash equivalents | $ 13,827 | $ 15,186 | |
Short term bank deposits | 43,579 | 45,975 | |
Other receivables and prepaid expenses | 1,934 | 1,527 | |
Total current assets | 59,340 | 62,688 | |
Non-current assets | |||
Long term prepaid expenses | 864 | 908 | |
Property and equipment, net | 358 | 357 | |
Restricted cash | 85 | 55 | |
Operating lease right-of-use assets | 309 | 345 | |
Total non-current assets | 1,616 | 1,665 | |
Total assets | 60,956 | 64,353 | |
Current liabilities | |||
Trade payables | 1,487 | 1,336 | |
Accrued expenses | 1,248 | 555 | |
Employee and related expenses | 666 | 653 | |
Operating lease liabilities | 116 | 106 | |
Total current liabilities | 3,517 | 2,650 | |
Non-current liabilities | |||
Operating lease liabilities - long term | 203 | 237 | |
Total non-current liabilities | 203 | 237 | |
Commitments and contingent liabilities | |||
Total liabilities | 3,720 | 2,887 | |
Shareholders' equity | |||
Ordinary shares no par value - Authorized: 650,000,000 shares as of March 31, 2022 and as of December 31, 2021; Issued and outstanding: 228,090,300 ordinary shares at March 31, 2022 as of December 31, 2021 | 0 | 0 | |
Additional paid in capital | 98,513 | 97,639 | |
Accumulated deficit | (41,277) | (36,173) | |
Total shareholders' equity | 57,236 | 61,466 | [1] |
Total liabilities and shareholders' equity | $ 60,956 | $ 64,353 | |
[1] | Number and type of equity instruments reflects the capital of the legal parent (the Company). |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Common Stock, No Par Value | $ 0 | $ 0 |
Common Stock, Shares Authorized | 650,000,000 | 650,000,000 |
Common Stock, Shares, Issued | 228,090,300 | 228,090,300 |
Common Stock, Shares, Outstanding | 228,090,300 | 228,090,300 |
Condensed Consolidated Interim
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | ||
Operating expenses | |||
Research and development | $ 2,745 | $ 1,157 | |
General and administrative | 2,575 | 542 | |
Total operating expenses | 5,320 | 1,699 | |
Financing expenses (income), net | (216) | 5 | |
Net loss for the period | $ 5,104 | $ 1,704 | |
Basic and diluted loss per Ordinary Share | [1] | $ 0.022 | $ 0.011 |
Weighted average number of Ordinary Shares outstanding, basic, and diluted | [1] | 228,090,300 | 156,751,771 |
[1] | Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer’s shareholders in the reverse recapitalization transaction (refer to Note 1B). |
Condensed Consolidated Interi_2
Condensed Consolidated Interim Statements of Changes in Equity (Unaudited) - USD ($) $ in Thousands | Ordinary shares [Member] | Additional paid in capital [Member] | Accumulated deficit [Member] | Total | |
Beginning balance at Dec. 31, 2020 | [1] | $ 0 | $ 34,497 | $ (23,695) | $ 10,802 |
Beginning balance (in shares) at Dec. 31, 2020 | [1] | 9,274,838 | |||
Share-based compensation | $ 0 | $ 43 | $ 0 | $ 43 | |
Effect of reverse capitalization transaction | - | 2,476 | - | 2,476 | |
Effect of reverse capitalization transaction (in shares) | 152,299,702 | ||||
Issuance of shares and warrants, net of issuance costs | $ 0 | $ 43,547 | $ 0 | $ 43,547 | |
Issuance of shares and warrants, net of issuance costs (In shares) | 52,385,400 | ||||
Net loss for the period | $ 0 | 0 | (1,704) | (1,704) | |
Ending balance at Mar. 31, 2021 | $ 0 | 80,563 | (25,399) | 55,164 | |
Ending balance (in shares) at Mar. 31, 2021 | 213,959,940 | ||||
Beginning balance at Dec. 31, 2021 | [2] | $ 0 | 97,639 | (36,173) | 61,466 |
Beginning balance (in shares) at Dec. 31, 2021 | [2] | 228,090,300 | |||
Share-based compensation | $ 0 | 874 | 0 | 874 | |
Net loss for the period | 0 | 0 | (5,104) | (5,104) | |
Ending balance at Mar. 31, 2022 | $ 0 | $ 98,513 | $ (41,277) | $ 57,236 | |
Ending balance (in shares) at Mar. 31, 2022 | 228,090,300 | ||||
[1] | Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B). | ||||
[2] | Number and type of equity instruments reflects the capital of the legal parent (the Company). |
Condensed Interim Statements of
Condensed Interim Statements of Cash flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Cash flows from operating activities | ||
Net loss for the period | $ (5,104) | $ (1,704) |
Adjustments for operating activities: | ||
Depreciation | 13 | 7 |
Change in other receivables and prepaid expenses | (363) | 57 |
Change in operating lease liability | 12 | 0 |
Change in trade payables | 151 | 281 |
Change in accrued expenses | 693 | (62) |
Change in employees and related expenses | 13 | 85 |
Share-based compensation | 874 | 43 |
Adjustments for operating activities | 1,393 | 411 |
Net cash used in operating activities | (3,711) | (1,293) |
Cash flows from investing activities | ||
Investment in deposits | 2,396 | 1 |
Purchase of property and equipment | (14) | (3) |
Net cash provided by (used in) investing activities | 2,382 | (2) |
Cash flows from financing activities | ||
Cash acquired in reverse recapitalization | 0 | 2,427 |
Issuance of shares and warrants, net of issuance costs | 0 | 45,372 |
Net cash provided by financing activities | 0 | 47,799 |
Change in cash, cash equivalents and restricted cash | (1,329) | 46,504 |
Cash, cash equivalents and restricted cash at beginning of period | 15,241 | 11,727 |
Cash, cash equivalents and restricted cash at end of period | 13,912 | 58,231 |
Supplemental disclosure of non-cash investing and financing activities: | ||
Liabilities assumed, net of non-cash assets received in reverse merger | 0 | 49 |
Accrued share issuance expenses | $ 0 | $ 1,825 |
General
General | 3 Months Ended |
Mar. 31, 2022 | |
General. | |
General. | Note 1 - General. A. Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli based company incorporated under the laws of the State of Israel in September 2011. The Company’s registered office is located in Kiryat Atidim, Tel Aviv, Israel. The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis. B. On March 16, 2021, the Company, then known as Anchiano Therapeutics Ltd. (“Anchiano”), completed its merger with Chemomab Ltd., a privately-held Israeli limited company (“Chemomab Ltd.”). Pursuant to the Agreement and Plan of merger (the “Merger Agreement”) dated as of December 14, 2020, by and among Anchiano, CMB Acquisition Ltd., an Israeli limited company and wholly-owned subsidiary of Anchiano (“Merger Sub”), and Chemomab Ltd. Upon completion of the merger transaction, pursuant to which Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. being the surviving entity and a wholly owned subsidiary of Anchiano (the “Merger”), the Company changed its name from “Anchiano Therapeutics Ltd.” to “Chemomab Therapeutics Ltd.” and the business conducted by Chemomab Ltd. became the primarily business conducted by the Company. For accounting purposes, Chemomab Ltd. is considered to have acquired Anchiano based upon the terms of the Merger as well as other factors including; (i) Chemomab Ltd.'s former shareholders owned approximately 90% of the combined Company’s outstanding ordinary shares immediately following the closing of the Merger, and (ii) Chemomab Ltd. management holds key management positions of the combined Company. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger. Immediately prior to the effective date of the Merger, all preferred shares of Chemomab Ltd. were converted into ordinary shares of Chemomab Ltd. on a one-for-one basis. In connection with the Merger, and following the effective time of the Merger, the Company effected a reverse share split of its ordinary shares at a ratio of 4:1 (the “Reverse Split”) and increased the number of ordinary shares underlying each American Depositary Share ("ADS") from 5 to 20. At the effective time of the Merger, each Chemomab Ltd. ordinary share outstanding immediately prior to the effective time of the Merger automatically converted into the right to receive approximately 12.86 ADSs, each representing 20 ordinary shares of the Company, plus a warrant to purchase ADSs that may become exercisable only under certain circumstances (the “exchange ratio”). The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and unvested, under the Chemomab Share Incentive Plan (the “2015 Plan”), with such options representing the right to purchase a number of ADSs equal to approximately 12.86 multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options. The accompanying unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements give retroactive effect to the exchange ratio and the Reverse Split for all periods presented. The equity structure reflects the legal acquirer's equity structure. The balance sheet has been adjusted to reflect the par value of the outstanding shares of the legal acquirer, including the number of shares issued in the Merger. Any difference is recognized as an adjustment to the additional paid in capital. Immediately after completion of the Merger, on March 16, 2021, the Company had 8,078,727 ADS issued and outstanding (9,003,357 on a fully diluted basis). In addition, immediately after the Merger, Chemomab Ltd. former shareholders owned approximately 90% of the number of issued and outstanding ordinary shares of the Company and the shareholders of the Company immediately prior to the Merger owned approximately 10% of the number of issued and outstanding ordinary shares of the Company (all on a fully diluted basis). On March 16, 2021, immediately prior to the effectiveness of the Merger, Anchiano had 65,675,904 ordinary shares outstanding (prior to the effect of the Reverse Split) and a market capitalization of $58.7 million. The estimated fair value of the net assets of Anchiano on March 16, 2021, prior to the Merger, was approximately $2.5 million. The fair value of ordinary shares on the Merger closing date, prior to the Merger, was above the fair value of the Company’s net assets. As the Company’s net assets were predominantly composed of cash offset against current liabilities, the fair value of the Company’s net assets as of March 16, 2021, immediately prior to the Merger, was considered to be the best indicator of the fair value and, therefore, the estimated preliminary purchase consideration. The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in thousands): Cash and cash equivalents $ 2,427 Asset held for sale 1,000 Prepaid and other assets 236 Accrued liabilities (1,187 ) Net acquired assets $ 2,476 C. In connection with the Merger, on March 15, 2021, Anchiano entered into Securities Purchase Agreements with certain purchasers for the issuance and sale by Anchiano in a private placement (“Private Placement”) of approximately $45.5 million of its ADSs and accompanying warrants to purchase ADSs. The warrants have an exercise price of approximately $17.35 per ADS, expire five years from the date of issuance, and if exercised in full will provide additional proceeds to the Company of $4.5 million. The closing of the Private Placement was completed on March 22, 2021. D. Pursuant to an Asset Purchase and Assignment Agreement dated as of March 16, 2021, as amended on March 31, 2021, between the Company’s wholly owned subsidiary, Anchiano Therapeutics, Inc., a Delaware corporation (“Anchiano Delaware”) and Kestrel Therapeutics, Inc., a company organized under the laws of Delaware (“Kestrel”), Anchiano Delaware agreed to sell to Kestrel all of the its rights and obligations in its business to the extent related to the research, development and commercialization of the Compounds and Products (as such terms are defined in the Collaboration and License Agreement entered into as of September 13, 2019, by and between ADT Pharmaceuticals, LLC and the Anchiano Delaware), also known as the pan-RAS and PDE10/β-catenin programs. In consideration of the sale and transfer of the Compounds and Products Kestrel paid the Company a total of $1.0 million. E. On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM agreement") with Cantor Fitzgerald & Co., ("Cantor"). Pursuant to the ATM agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $75 million through Cantor or the ATM agreement. From April 30, 2021 through March 31, 2022, the Company issued 699,806 ADSs at an average price of $22.75 per ADS through the ATM Prospectus Supplement, resulting in gross proceeds of $15.9 million. The offer and sale of ADSs under the ATM agreement has been registered under the Company’s effective registration statement on Form S-3 (File No. 333-255658), together with a prospectus forming a part thereof, filed with the SEC under the Securities Act of 1933, as amended (the “Securities Act”). Sales, if any, of ADS pursuant to the ATM agreement may be made in any transactions that are deemed to be “at the market” offerings as defined in Rule 415(a)(4) under the Securities Act. The Company is not obligated to sell any ADSs under the ATM agreement. On April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000 of the Company's ADSs (instead of the amount of $75 million above) in connection with the reactivation of the ATM Facility. F. Since January 2020, the COVID-19 outbreak has dramatically expanded into a worldwide pandemic creating macro-economic uncertainty and disruption in the business and financial markets. Many countries around the world, including Israel, have been taking measures designated to limit the continued spread of the Coronavirus, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the enrollment of Company’s clinical trials of CM-101 in PSC was delayed and the enrollment rate has been affected as well. As a result, the Company extended patient recruiting to additional territories with significant recruitment potential. In addition, after enrollment in these trials, patients may drop out of the Company's trials because of the COVID-19 possible implications. Based on management’s assessment, the extent to which the coronavirus will further impact the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. The Company is carefully monitoring the restrictions due to the COVID-19 outbreak and will adjust activities accordingly. |
Basis of Presentation and Signi
Basis of Presentation and Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Significant Accounting Policies | Note 2 - Basis of Presentation and Significant Accounting Policies A. Basis of Preparation The condensed interim consolidated financial statements included in this quarterly report are unaudited. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company’s financial position as of March 31, 2022, and its results of operations for the three months ended March 31, 2022, and 2021, changes in shareholders’ equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company’s Form 10-K for the year ended December 31, 2021 as filed with the SEC. The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2021 included in the Company’s Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies. B. Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. |
Basis of Presentation and Sig_2
Basis of Presentation and Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Basis of Preparation | A. Basis of Preparation The condensed interim consolidated financial statements included in this quarterly report are unaudited. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company’s financial position as of March 31, 2022, and its results of operations for the three months ended March 31, 2022, and 2021, changes in shareholders’ equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company’s Form 10-K for the year ended December 31, 2021 as filed with the SEC. The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2021 included in the Company’s Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies. |
Use of estimates | B. Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. |
General (Tables)
General (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
General. | |
Schedule of net assets acquired based on their estimated fair value | Cash and cash equivalents $ 2,427 Asset held for sale 1,000 Prepaid and other assets 236 Accrued liabilities (1,187 ) Net acquired assets $ 2,476 |
General (Detail Textuals)
General (Detail Textuals) | Mar. 16, 2021USD ($)shares | Mar. 15, 2021USD ($)$ / shares | Apr. 25, 2022USD ($) | Apr. 30, 2021USD ($) | Mar. 31, 2022USD ($)$ / shares | Mar. 31, 2021USD ($) | Mar. 31, 2022USD ($)$ / sharesshares |
Restructuring Cost and Reserve [Line Items] | |||||||
Number of common shares for each preferred share converted | shares | 1 | ||||||
Reverse stock split conversion ratio | 0.04 | ||||||
Market capitalization amount | $ 58,700,000 | ||||||
Share-based compensation expense | $ 874,000 | $ 43,000 | |||||
Isuuance and sale value of ADSs and warrants | $ 45,500,000 | ||||||
Warrant exercise price | $ / shares | $ 17.35 | ||||||
Warrants exercisable period | 5 years | ||||||
Proceeds from exercise of warrants | $ 4,500,000 | ||||||
Amount of total sale and transfer of compounds and products kestrel paid | $ 1,000,000 | ||||||
American Depository Shares ADSs [Member] | At the Market Offering Agreement with Cantor Fitzgerald & Co. [Member] | |||||||
Restructuring Cost and Reserve [Line Items] | |||||||
Aggregate offering price | $ 75,000,000 | ||||||
Shares issued under agreement | shares | 699,806 | ||||||
Average price of shares issued under agreement | $ / shares | $ 22.75 | $ 22.75 | |||||
Gross proceeds from sale under agreement | $ 15,900,000 | ||||||
American Depository Shares ADSs [Member] | At the Market Offering Agreement with Cantor Fitzgerald & Co. [Member] | Subsequent Event [Member] | |||||||
Restructuring Cost and Reserve [Line Items] | |||||||
Gross proceeds from sale under agreement | $ 18,125,000 | ||||||
Former Chemomab Security Holders [Member] | |||||||
Restructuring Cost and Reserve [Line Items] | |||||||
Shareholding percentage immediately following the merger | 90.00% | ||||||
Number of common shares for each preferred share converted | shares | 65,675,904 | ||||||
Accumulated deficit | $ 2,500,000 | ||||||
Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member] | |||||||
Restructuring Cost and Reserve [Line Items] | |||||||
Number of ordinary shares represented by each ADS (in shares) | shares | 20 | ||||||
Number of ADS issued and outstanding after the merger | shares | 12.86 | ||||||
Number of shares diluted after the merger | shares | 8,078,727 | ||||||
Number of shares after merger for each share of Chemomab | shares | 9,003,357 |
General - Estimated fair value
General - Estimated fair value of assets acquired (Details) $ in Thousands | Mar. 16, 2021USD ($) |
General. | |
Cash and cash equivalents | $ 2,427 |
Asset held for sale | 1,000 |
Prepaid and other assets | 236 |
Accrued liabilities | (1,187) |
Net acquired assets | $ 2,476 |